Pharmaceuticals News and Research

RSS

CorMedix to primarily focus on commercialization of Neutrolin in Europe

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has decided based upon recent developments to primarily focus on the commercialization of Neutrolin in Europe.

1 Oct 2011

MDC Partners acquires majority stake in Concentric Pharma

Concentric Pharma Advertising, one of the largest and fastest-growing healthcare advertising agencies in the country, announced today that MDC Partners, Inc., has acquired a majority stake in the company.

1 Oct 2011

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Express Scripts has launched a suite of services for pharmaceutical and biotech companies through HealthBridge Pharma & Biotech, providing a single-solution approach to patient care.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Novel binding assay can simplify search for potential SERT inhibitors

Many psychiatric conditions are caused by aberrant metabolism of the neurotransmitter serotonin. Researchers in the Department of Pharmacy at LMU have now developed a new screening method, which will facilitate the search for new drugs that modulate the biological activity of serotonin.

1 Oct 2011

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

ADVENTRX Pharmaceuticals, Inc. announced today that it held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) it received in August from the FDA regarding the Company's New Drug Application (NDA) for Exelbine (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.

1 Oct 2011

Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J.

Roche announced today the opening of a new state-of-the-art clinical supply manufacturing facility on its campus in Nutley, N.J. The Roche Center of Excellence produces dosage forms of highly potent compounds for preclinical safety studies, and Phase 1 and 2 clinical studies.

30 Sep 2011

Takeda acquires Nycomed

Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced it has completed its acquisition of Nycomed A/S for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations, Takeda Pharmaceuticals International, Inc., a wholly owned subsidiary of Takeda America Holdings, Inc.

30 Sep 2011

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how scientific findings from St. Jude can be translated into therapies and tests that in addition to helping children, also help adults.

30 Sep 2011

FDA, other regulatory and international partners complete International Internet Week of Action

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

30 Sep 2011

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

30 Sep 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

Poor hospital supplies could spell danger for vulnerable patients

It was found that most hospitals operate with less than a month's supply of many essential medicines, leaving patients vulnerable if local distributors are unable to import them through fragile international supply chains.

29 Sep 2011

Bulgaria’s decades old anti-smoking pill could be a cheap and effective answer to smoking cessation

A pill from Bulgaria during the Soviet era shows promise for helping millions of smokers cheaply and safely kick the habit, the first big clinical trial of it shows. It is unclear whether it will ever reach the market in the U.S. or Western Europe though.

29 Sep 2011

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

29 Sep 2011

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.

29 Sep 2011

New process makes linear peptides circular

Peptides and proteins have long been an attractive class of drug candidates because of their natural involvement in cellular processes and fewer potential side effects. Dr. Andrei Yudin, Professor, Department of Chemistry, University of Toronto, has developed a new and effective process that makes linear peptides circular, which allows these molecules, called macrocycles, to enter cells more effectively and increase their stability compared to linear peptides.

29 Sep 2011

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

29 Sep 2011

Public lecture on children's medicines to be launched on October 5

The University of Greenwich's School of Science launches its public lecture series for the new academic year with an event at the Medway Campus on Wednesday, October 5.

29 Sep 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011